Price Control and Shorter Patent Terms to Affect Biotech Industry


Jul 08, 2013

The Baltimore Sun

Proposals to impose price controls on Medicare's prescription drug program and to shorten the patent-protection period for biologics could stifle innovation and make biotech firms hesitant to spend money on drug discovery and development, writes Scott Eldridge of Florida-based contract chemistry lab Global Pharma Analytics. Controlling the prices Medicare pays for drugs would "reduce manufacturers' incentives to invest in R&D on products that would be expected to have significant Medicare sales," according to the Congressional Budget Office. Read the full story.